Perimyocarditis secondary to pegylated interferon alpha 2a in chronic hepatitis C

Authors

  • Echeikh Myriam Department of Gastroenterology, Habib Thameur Hospital, Tunis
  • Kochlef Asma Department of Gastroenterology, Habib Thameur Hospital, Tunis
  • Elloumi Hela Department of Gastroenterology, Habib Thameur Hospital, Tunis
  • Battikh Kais Department of Gastroenterology, Habib Thameur Hospital, Tunis
  • Abdennebi BelHassen Department of Cardiology, Habib Thameur Hospital, Tunis
  • Gargouri Dalila Department of Cardiology, Habib Thameur Hospital, Tunis
  • Kharrat Jamel Department of Cardiology, Habib Thameur Hospital, Tunis
  • Ghorbel Abdeljabbar Department of Cardiology, Habib Thameur Hospital, Tunis

Keywords:

Hepatitis C

Abstract

Treatment of chronic hepatitis C is based on combination of pegylated interferon with ribavirin. There are many adverse effects of pegylated interferon which can lead to stop the treatment definitively. Cardiovascular toxicity of pegylated interferon was rarely described in chronic hepatitis C. We report the case of perimyocarditis due to pegylated interferon used with ribavirin during the treatment of chronic hepatitis C

International Journal of Hepatology Vol.1(3) 2010 pp.44-45

Downloads

Download data is not yet available.
Abstract
104
PDF
120

Downloads

Published

2010-11-29

How to Cite

Myriam, E., Asma, K., Hela, E., Kais, B., BelHassen, A., Dalila, G., Jamel, K., & Abdeljabbar, G. (2010). Perimyocarditis secondary to pegylated interferon alpha 2a in chronic hepatitis C. International Journal of Hepatology, 1(3), 44–45. Retrieved from https://banglajol.info/index.php/IJH/article/view/6567

Issue

Vol. 1 No. 3 (2010)

Section

Case Reports